BACKGROUND: The double stopwatch (DSW) method for determining the onset of analgesic activity has been implemented extensively by investigators studying orally administered drugs. OBJECTIVE: The aim of this randomised, placebo-controlled trial was to use the DSW method to determine the time to onset of analgesia of a single dose of a topically administered non-steroidal anti-inflammatory drug, flurbiprofen 8.75 mg lozenge. METHODS: Adults with acute sore throat (n = 122) were examined to confirm the presence of tonsillopharyngitis (Tonsillo-Pharyngitis Assessment) and sore throat pain of at least moderate intensity (≥6 on a 0-10 Sore Throat Scale). Lozenges containing flurbiprofen 8.75 mg or inert ingredients (identically flavoured) were administered under double-blind conditions in the clinic while patients assessed pain and pain relief over 3 hours. Onset of analgesia was determined using the DSW method and reported as the Kaplan-Meier median time to meaningful relief. The median time to first perceived relief was also documented. RESULTS: About 78% of flurbiprofen-treated patients reported meaningful pain relief compared with 48% of placebo-treated patients (p < 0.01); median time to meaningful relief for flurbiprofen-treated patients was 43 minutes (placebo-treated patients were right-censored due to non-responsivity; p = 0.01). Median time to first perceived pain relief was 11 minutes for flurbiprofen-treated patients and 19 minutes for placebo-treated patients (p = 0.03). Flurbiprofen lozenge was well tolerated, with no serious adverse events occurring and no patient discontinuing due to an adverse event. CONCLUSION: These results indicate that the DSW method can be successfully applied to the evaluation of the onset of action of a locally administered analgesic in patients with acute sore throat, demonstrating that the onset of action (time to meaningful pain relief) of flurbiprofen lozenge was <45 minutes.
BACKGROUND: The double stopwatch (DSW) method for determining the onset of analgesic activity has been implemented extensively by investigators studying orally administered drugs. OBJECTIVE: The aim of this randomised, placebo-controlled trial was to use the DSW method to determine the time to onset of analgesia of a single dose of a topically administered non-steroidal anti-inflammatory drug, flurbiprofen 8.75 mg lozenge. METHODS: Adults with acute sore throat (n = 122) were examined to confirm the presence of tonsillopharyngitis (Tonsillo-Pharyngitis Assessment) and sore throat pain of at least moderate intensity (≥6 on a 0-10 Sore Throat Scale). Lozenges containing flurbiprofen 8.75 mg or inert ingredients (identically flavoured) were administered under double-blind conditions in the clinic while patients assessed pain and pain relief over 3 hours. Onset of analgesia was determined using the DSW method and reported as the Kaplan-Meier median time to meaningful relief. The median time to first perceived relief was also documented. RESULTS: About 78% of flurbiprofen-treated patients reported meaningful pain relief compared with 48% of placebo-treated patients (p < 0.01); median time to meaningful relief for flurbiprofen-treated patients was 43 minutes (placebo-treated patients were right-censored due to non-responsivity; p = 0.01). Median time to first perceived pain relief was 11 minutes for flurbiprofen-treated patients and 19 minutes for placebo-treated patients (p = 0.03). Flurbiprofen lozenge was well tolerated, with no serious adverse events occurring and no patient discontinuing due to an adverse event. CONCLUSION: These results indicate that the DSW method can be successfully applied to the evaluation of the onset of action of a locally administered analgesic in patients with acute sore throat, demonstrating that the onset of action (time to meaningful pain relief) of flurbiprofen lozenge was <45 minutes.
Authors: Stanford T Shulman; Alan L Bisno; Herbert W Clegg; Michael A Gerber; Edward L Kaplan; Grace Lee; Judith M Martin; Chris Van Beneden Journal: Clin Infect Dis Date: 2012-11-15 Impact factor: 9.079
Authors: Bernard P Schachtel; Sharon Pan; Joseph D Kohles; Kathleen M Sanner; Emily P Schachtel; Mary Bey Journal: J Clin Pharmacol Date: 2007-05-24 Impact factor: 3.126
Authors: Bernard Schachtel; Sue Aspley; Adrian Shephard; Timothy Shea; Gary Smith; Emily Schachtel Journal: Trials Date: 2014-07-03 Impact factor: 2.279
Authors: Martin C Gulliford; Alex Dregan; Michael V Moore; Mark Ashworth; Tjeerd van Staa; Gerard McCann; Judith Charlton; Lucy Yardley; Paul Little; Lisa McDermott Journal: BMJ Open Date: 2014-10-27 Impact factor: 2.692
Authors: Rob Turner; Sean Robert Wevrett; Suzanne Edmunds; Marc B Brown; Robert Atkinson; Oluwajoba Adegoke; Anuradha Kulasekaran; Tim Shea Journal: Clin Pharmacol Date: 2020-03-24
Authors: Rob Turner; Sean Robert Wevrett; Suzanne Edmunds; Marc Brown; Anuradha Kulasekaran; Oluwajoba Adegoke; John Farrah Journal: Clin Pharmacol Date: 2021-01-19
Authors: Rob Turner; Sean Robert Wevrett; Suzanne Edmunds; Marc Brown; Robert Atkinson; Tim Shea Journal: Biomed Chromatogr Date: 2019-05-06 Impact factor: 1.902